| Optimal treatment with boceprevir for chronic HCV infection. | |
| | |
MedLine Citation:
|
PMID: 23286841 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
There are 160-170 million people with chronic hepatitis C virus (HCV) infection worldwide. The marketing of protease inhibitors (PIs) has been a milestone in the history of HCV therapy. In phase III studies, up to 75% of the patients achieved a sustained virological response (SVR) after triple therapy with pegylated-interferon (PEG-IFN)-α, ribavirin (RBV) and boceprevir (BOC). However, triple regimens are more expensive and associated with drug-drug interactions (DDIs) and more adverse events (AEs). According to results in 'real-world' settings, safety seems to be limited, in particular in patients with advanced liver disease. To optimize efficacy while minimizing AEs as well as costs, the optimal treatment strategy must be determined for BOC. Optimizing treatment is based on patient selection, the most efficient treatment design, management of side effects and the challenge of DDIs. Therapy-associated risks, treatment urgency and chances of SVR must all be considered for patient selection. In addition, certain differences between the two approved PIs may help identify the ideal candidates for each HCV PI. Optimal treatment design is based on the results of phase II and III studies, in which different approaches have been tested including 'lead-in' and response-guided strategies. Treatment regimens and stopping rules recommended by the FDA and EMA should normally be followed. Still, there are some cases in which more personalized strategies may be more promising. Management of side effects is a major challenge and plays a crucial role in ensuring safety and adherence. |
| | |
Authors:
|
Benjamin Maasoumy; Michael P Manns |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver international : official journal of the International Association for the Study of the Liver Volume: 33 Suppl 1 ISSN: 1478-3231 ISO Abbreviation: Liver Int. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-01-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160857 Medline TA: Liver Int Country: United States |
Other Details:
|
Languages: eng Pagination: 14-22 Citation Subset: IM |
Copyright Information:
|
© 2012 John Wiley & Sons A/S. |
Affiliation:
|
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimal treatment with telaprevir for chronic HCV infection.
Next Document: How to optimize HCV therapy in genotype 1 patients: predictors of response.